LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cotinine Assay Rapidly Confirms Nonsmoking Status

By LabMedica International staff writers
Posted on 13 Jan 2014
Print article
Image: The Saliva SmokeScreen test includes a saliva collecting device which consists of a white collecting swab and vial (Photo courtesy of GFC Diagnostics).
Image: The Saliva SmokeScreen test includes a saliva collecting device which consists of a white collecting swab and vial (Photo courtesy of GFC Diagnostics).
Image: Development of a pink color indicates a positive Saliva Smokescreen result (Photo courtesy of GFC Diagnostics).
Image: Development of a pink color indicates a positive Saliva Smokescreen result (Photo courtesy of GFC Diagnostics).
A novel, rapid and user-friendly diagnostic test provides confirmation that an individual has stopped smoking tobacco cigarettes.

In addition to being healthier, not smoking can significantly reduce the cost of health insurance. However, until recently it has not been easy to prove diagnostically that an individual was a non-smoker.

Toward this end, the British biotech company GFC Diagnostics (Bicester, United Kingdom) has introduced the Saliva SmokeScreen test. The test detects cotinine, a breakdown product of nicotine. Cotinine has an in vivo half-life of approximately 20 hours, and is typically detectable for several days (up to one week) after the use of tobacco. The level of cotinine in the blood is proportionate to the amount of exposure to tobacco smoke, so it is a valuable indicator of tobacco smoke exposure. The newly improved Saliva SmokeScreen assay is more sensitive and specific than its previous version, being reported at 90% and 98% respectively, with an accuracy of 94%.

To test for nicotine exposure the user places the test swab in the mouth to absorb 1.5 mL of saliva. The swab is removed from the mouth, placed inside the plastic collector, and pushed against the grid half way down. This procedure squeezes the saliva into the bottom of the collector. The presence of cotinine causes a color change that is visible after one minute. The optimal time to read the result is six minutes. If read before five minutes, the result will be positive, but less than the correct result. After six minutes, it will be more than the true result.

The Saliva SmokeScreen test has been certified as a tool in a British health insurer's program to verify nonsmoking in their policy holders, so they can qualify for its unique nonsmoker cash back reward. Dr. Graham Cope, technical director at GFC Diagnostics and an honorary senior research fellow at the University of Birmingham (United Kingdom), said, "Smoking is an important risk factor for many chronic diseases, such as respiratory diseases, cardiovascular disease, and diabetes. It also causes blood pressure to rise and is linked with high cholesterol levels. We are pleased the SmokeScreen test has been chosen as the means to monitor smoking in this program."

Related Links:

GFC Diagnostics
University of Birmingham


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more